. . . . . . . "[Although samples enriched for APOE ?4 carriers in AD or MCI clinical trials showed slightly more cognitive impairment and greater decline using the number APOE ?4 alleles as an inclusion criterion most likely would not result in more efficient trials, and trials would take longer because fewer patients would be available.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:10:35+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .